Ann: Investor Presentation, page-335

First 335 Last

Share
Profile

Follow
Blinger

216 Posts.

35

08/06/24

19:35

Post #: 74232167
Share

Originally posted by Bazsa: ↑

First , considering this patent was fron 2005 I would say there was not any need to defend the claim. MSB withdrew the claims made in the patent that was all most expired anyway.Could I suggest that a much newer version probably around 2018 would be a fair bit stronger in its claims. That patent would also have Oaktree on it. Obviously they didn't think it was valueless.

https://patents.google.com/patent/US11180733B2/enWhat were these guys thinking? Probably the same as SI and crew. IP protection is a must, without it you have nothing. Did you have a look, what if your cells work in OA. I would bet they will be a little bit interested with $$$ in sight.

You bring up Tigenix now Takeda and comments made around what was some very handy $$$ for MSB and what may have been some very handy revenue of around 10% of sales. Again we see the value of patents and if you believe them it was just for a additional layer of protection. Protection for them if by chance someone like CYP may come along with a like product and approach on there turf.

Now for your only results , GVHD
Yes Water would show just as good results as your cells have.
I don't see the grade 4s

A nice fluff chart. The data only shows best response

I will be kind and recognise the imperfections of the grading system. Lets say 40% of the above have a really bad mortality rate, 90%. The other 60% have a very good outcome, around 10 % mortality . Put together the overall mortality rate would work out to be 42% inline with what you would expect from water.

Trials by there nature can fail to show positive results. MSB have seen plenty. The odd miracle may not show up in the results yet have a profound impact on the investigating team. They would do anything to save a life including asking for companional use of the drug. Is it that CYP have not been asked (results just didn't show that miracle) or CYP too tight to even give up a few so called cheap cells to save a life ?

Expand

Bazsa - Have you realized you are at the bottom of the table on well, everything

"Trials by there nature can fail to show positive results. MSB have seen plenty."

Yes, we still follow you here

CYP Price at posting: 30.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

AUG

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

TX3

Canadian fieldwork yields multiple pegmatites for Trinex

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

RNU

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

TLX

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

There are more pages in this discussion • 275 more messages in this thread...

First 335 Last

Add CYP (ASX) to my watchlist

(20min delay)
Last 25.0¢		Change -0.010(3.85%)		Mkt cap ! $44.90M

Open	High	Low	Value	Volume
26.0¢	26.5¢	25.0¢	$5.869K	22.42K

Buyers (Bids)

No.	Vol.	Price($)
1	29342	25.0¢

Sellers (Offers)

Price($)	Vol.	No.
27.0¢	30000	1

View Market Depth

No.	Vol.	Price($)
1	29342	0.250
2	31297	0.245
4	107225	0.240
1	100000	0.235
2	15173	0.230

Price($)	Vol.	No.
0.270	30000	1
0.290	7125	3
0.295	183892	1
0.300	85000	2
0.310	16591	3

Last trade - 15.47pm 11/07/2024 (20 minute delay)

CYP (ASX) Chart

Ann: Investor Presentation, page-335

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Canadian fieldwork yields multiple pegmatites for Trinex

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor Presentation, page-335

Top Stories

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Canadian fieldwork yields multiple pegmatites for Trinex

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News